Evidence map›Paper›PMID 31570787›Full record

ArticleOncogene2020

Bile acid-induced "Minority MOMP" promotes esophageal carcinogenesis while maintaining apoptotic resistance via Mcl-1.

Yuan Xu, Deborah R Surman, Laurence Diggs, Sichuan Xi, Shaojian Gao, Devikala Gurusamy, Kaitlin McLoughlin, Justin Drake, Paul Feingold, Kate Brown and 10 more

Open access · greenAbstract read
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Yuan XuCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Deborah R SurmanCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Laurence DiggsCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Sichuan XiCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Shaojian GaoCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Devikala GurusamySurgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Kaitlin McLoughlinCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-1442-1802
Justin DrakeCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-2500-7044
Paul FeingoldCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Kate BrownCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Danny WangsaGenetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Darawalee WangsaGenetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Xi ZhangDepartment of Medicine, Center for Esophageal Diseases, Baylor University Medical Center and Center for Esophageal Research, Baylor Scott and White Research Institute, Dallas, TX, USA.
Thomas RiedGenetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Jeremy L DavisCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Jonathan HernandezCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Chuong D HoangCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Rhonda F SouzaDepartment of Medicine, Center for Esophageal Diseases, Baylor University Medical Center and Center for Esophageal Research, Baylor Scott and White Research Institute, Dallas, TX, USA.
David S SchrumpCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
R Taylor RipleyCenter for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA. R.Taylor.Ripley@bcm.edu.
National Cancer Institute · USBaylor University Medical Center · USBaylor College of Medicine · USMichael E. DeBakey VA Medical Center · US

Funding

Modulating Cancer Stem Cell Signaling in Thoracic MalignanciesZIABC011418 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHRUMP, DAVID · 2011 to 2025
$17.4M
Epigenetic Mechanisms of Gene Expression in Thoracic MalignanciesZIABC011115 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHRUMP, DAVID · 2009 to 2025
$15.1M
Intratumor heterogeneity and tumor evolutionZIABC010834 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RIED, THOMAS · 2009 to 2023
$12.2M
Synergy of Bile Acid and Cigarette Smoke on Esophageal Cancer ProgressionZIABC011631 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RIPLEY, ROBERT · 2015 to 2018
$1.6M
Evaluating outcomes for patients with primary-metastatic gastrointestinal cancerZIABC011861 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HERNANDEZ, JONATHAN · 2019 to 2025
$166k
Intramural NIH HHS ZIA BC011115Intramural NIH HHS ZIA BC011631
6 · The paper itself

Abstract

Barrett's esophagus (BE) is associated with reflux and is implicated the development of esophageal adenocarcinoma (EAC). Apoptosis induces cell death through mitochondrial outer membrane permeabilization (MOMP), which is considered an irreversible step in apoptosis. Activation of MOMP to levels that fail to reach the apoptotic threshold may paradoxically promote cancer-a phenomenon called "Minority MOMP." We asked whether reflux-induced esophageal carcinogenesis occurred via minority MOMP and whether compensatory resistance mechanisms prevented cell death during this process. We exposed preneoplastic, hTERT-immortalized Barrett's cell, CP-C and CP-A, to the oncogenic bile acid, deoxycholic acid (DCA), for 1 year. Induction of minority MOMP was tested via comet assay, CyQuant, annexin V, JC-1, cytochrome C subcellular localization, caspase 3 activation, and immunoblots. We used bcl-2 homology domain-3 (BH3) profiling to test the mitochondrial apoptotic threshold. One-year exposure of Barrett's cells to DCA induced a malignant phenotype noted by clone and tumor formation. DCA promoted minority MOMP noted by minimal release of cytochrome C and limited caspase 3 activation, which resulted in DNA damage without apoptosis. Upregulation of the antiapoptotic protein, Mcl-1, ROS generation, and NF-κB activation occurred in conjunction with minority MOMP. Inhibition of ROS blocked minority MOMP and Mcl-1 upregulation. Knockdown of Mcl-1 shifted minority MOMP to complete MOMP as noted by dynamic BH3 profiling and increased apoptosis. Minority MOMP contributes to DCA induced carcinogenesis in preneoplastic BE. Mcl-1 provided a balance within the mitochondria that induced resistance complete MOMP and cell death. Targeting Mcl-1 may be a therapeutic strategy in EAC.

Indexed as

ApoptosisBarrett EsophagusBile Acids and SaltsCarcinogenesisCell LineCell Membrane PermeabilityCytochromes cDNA DamageEsophageal NeoplasmsEsophagusGastrointestinal AgentsHumansMitochondriaMyeloid Cell Leukemia Sequence 1 ProteinSignal TransductionBile Acids and SaltsCytochromes cGastrointestinal AgentsMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 Protein

Identifiers

PMID31570787
PMCPMC8366558
OpenAlexW2975585755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.